OXB, a global cell and gene therapy CDMO, has announced the acquisition of the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio. This move brings the company’s ownership of the US operation to 100%, as
Fujirebio Diagnostics, Inc., part of H.U. Group Holdings Inc., has completed the acquisition of all shares in Plasma Services Group, Inc., a company specialising in rare biological sample collection and supply for the in vitro diagnostics (IVD) and life science
Celltrion UK has officially launched its new UK headquarters at the Charter Building in Uxbridge, reinforcing its commitment to the British pharmaceutical and biotechnology sector. The opening ceremony was attended by Celltrion CEO and Vice Chairman Hyoung-Ki Kim, Rosalind Campion, Director
PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) focused on radiopharmaceuticals, has finalised its acquisition of a majority stake in Norway-based Agilera Pharma AS. The stake was acquired from the Institute for Energy Technology (IFE). The deal marks
Bionova Scientific, a contract development and manufacturing organisation (CDMO), has announced the installation of a third FlexFactory manufacturing platform from Cytiva as it enters the advanced therapy manufacturing space. The company aims to meet rising demand for genomic medicines while
Porton Pharma Solutions Ltd. has announced the successful completion of a Qualified Person (QP) audit at its Shanghai Fengxian Manufacturing Site, confirming the site’s compliance with EU GMP standards. The five-day audit, conducted by a German QP auditor, assessed quality systems,
Kindeva, a global CDMO specialising in drug-device combination products, has announced a collaboration with Canadian health technology company Rocket Science Health (RSH) to support the development of a novel intranasal delivery platform. The agreement aims to identify commercial and development
Delpharm, a contract development and manufacturing organisation (CDMO), has announced the commissioning of a new sterile filling line at its Saint-Rémy site in France. The investment supports national strategic goals for strengthening pharmaceutical manufacturing infrastructure. The total investment, which includes
Veranova has begun construction on a major expansion of its facility in Devens, Massachusetts, aimed at enhancing its capabilities in the development and production of complex therapies, including antibody-drug conjugates (ADCs). The groundbreaking event, held on 18 June 2025, brought together
Bend Bioscience has announced the opening of four additional process development and manufacturing suites at its Bend, Oregon facility, bringing the site’s total to seven cGMP suites dedicated to early-phase pharmaceutical manufacturing. The new 14,000-square-foot expansion enhances capabilities for oral and
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
